ten23 health Valais AGApril 24, 2019

FDA 483 - ten23 health Valais AG - April 24, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore ten23 health Valais AG

Record Details

Swissfillon AG, a contract drug manufacturer in Visp, Switzerland, was cited for significant deficiencies in its aseptic processing areas. The inspection revealed inadequate environmental monitoring procedures, leading to microbial growth exceeding acceptance criteria, and a lack of proper cleaning and gowning instructions, resulting in observed improper aseptic techniques and potential product contamination.

Company: ten23 health Valais AG
Inspection Date: April 24, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
People: Amir Alavi (investigator)
Jamie L. C. Dion

Open in Dashboard

ID · 63581208-7264-4919-ade7-fd1f2306a687